Suppr超能文献

新星崛起:神经内分泌前列腺癌中的异质性和肿瘤微环境。

RISING STARS: Heterogeneity and the tumor microenvironment in neuroendocrine prostate cancer.

机构信息

Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Center, Seattle, Washington, USA.

Division of Medical Oncology, University of Washington, Seattle, Washington, USA.

出版信息

J Endocrinol. 2022 Dec 22;256(2). doi: 10.1530/JOE-22-0211. Print 2023 Feb 1.

Abstract

Neuroendocrine prostate cancer, generally arising late in the disease trajectory, is a heterogeneous subtype that infers a worse prognosis and limited treatment options for patients. Characterization of the complex landscape of this disease subtype and scrutiny of the relationship between tumor cells and cells of the surrounding tumor microenvironment have aided in elucidating some of the mechanisms of neuroendocrine disease biology and have uncovered a multitude of signaling pathways involved in disease transdifferentiation under therapeutic selection. In this review, we discuss current efforts to better understand the heterogeneous landscape of neuroendocrine prostate cancer and summarize research efforts to define the interplay between tumor cells and the microenvironment, with an emphasis on the immune component. Research efforts have uncovered several potential therapeutic approaches that may improve disease outcomes for patients diagnosed with neuroendocrine prostate cancer, including the potential for combination immunotherapies. However, additional research is required to fully address and exploit the contribution of tumor cell and microenvironment heterogeneity in developing effective treatment strategies.

摘要

神经内分泌前列腺癌通常在疾病进程后期出现,是一种异质性亚型,预示着患者预后较差,治疗选择有限。对这种疾病亚型的复杂特征进行描述,并仔细研究肿瘤细胞与周围肿瘤微环境细胞之间的关系,有助于阐明神经内分泌疾病生物学的一些机制,并揭示了在治疗选择下疾病转化涉及的多种信号通路。在这篇综述中,我们讨论了目前为更好地理解神经内分泌前列腺癌的异质性景观所做的努力,并总结了定义肿瘤细胞与微环境相互作用的研究工作,重点关注免疫成分。研究工作已经揭示了几种潜在的治疗方法,这些方法可能改善诊断为神经内分泌前列腺癌的患者的疾病结局,包括联合免疫疗法的潜力。然而,需要进一步的研究来充分解决和利用肿瘤细胞和微环境异质性在制定有效治疗策略方面的贡献。

相似文献

1
RISING STARS: Heterogeneity and the tumor microenvironment in neuroendocrine prostate cancer.
J Endocrinol. 2022 Dec 22;256(2). doi: 10.1530/JOE-22-0211. Print 2023 Feb 1.
2
Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation.
J Exp Clin Cancer Res. 2022 Feb 2;41(1):46. doi: 10.1186/s13046-022-02255-y.
3
Cancer-cell-intrinsic mechanisms shaping the immunosuppressive landscape of prostate cancer.
Asian J Androl. 2023 Mar-Apr;25(2):171-178. doi: 10.4103/aja202283.
4
[Neuroendocrine prostate cancer: Natural history, molecular features, therapeutic management and future directions].
Bull Cancer. 2017 Sep;104(9):789-799. doi: 10.1016/j.bulcan.2017.05.007. Epub 2017 Jun 30.
5
The β-Adrenergic Receptor Is a Molecular Switch for Neuroendocrine Transdifferentiation of Prostate Cancer Cells.
Mol Cancer Res. 2019 Nov;17(11):2154-2168. doi: 10.1158/1541-7786.MCR-18-0605. Epub 2019 Aug 8.
7
The evolving role of immune cells in prostate cancer.
Cancer Lett. 2022 Jan 28;525:9-21. doi: 10.1016/j.canlet.2021.10.027. Epub 2021 Oct 29.
8
Molecular insights into prostate cancer progression: the missing link of tumor microenvironment.
J Urol. 2005 Jan;173(1):10-20. doi: 10.1097/01.ju.0000141582.15218.10.
9
Understanding the tumor-immune microenvironment in prostate cancer.
Curr Opin Oncol. 2021 May 1;33(3):231-237. doi: 10.1097/CCO.0000000000000719.
10
Clinical and molecular features of treatment-related neuroendocrine prostate cancer.
Int J Urol. 2018 Apr;25(4):345-351. doi: 10.1111/iju.13526. Epub 2018 Feb 3.

引用本文的文献

2
Role of Tumor Microenvironment in Prostate Cancer Immunometabolism.
Biomolecules. 2025 Jun 6;15(6):826. doi: 10.3390/biom15060826.
3
Molecular pathways in reproductive cancers: a focus on prostate and ovarian cancer.
Cancer Cell Int. 2025 Feb 3;25(1):33. doi: 10.1186/s12935-025-03658-5.
4
Unraveling molecular characteristics and tumor microenvironment dynamics of neuroendocrine prostate cancer.
J Cancer Res Clin Oncol. 2024 Oct 16;150(10):462. doi: 10.1007/s00432-024-05983-0.
6
A new tumorgraft panel to accelerate precision medicine in prostate cancer.
Front Oncol. 2023 May 26;13:1130048. doi: 10.3389/fonc.2023.1130048. eCollection 2023.

本文引用的文献

1
B7-H3 as a Therapeutic Target in Advanced Prostate Cancer.
Eur Urol. 2023 Mar;83(3):224-238. doi: 10.1016/j.eururo.2022.09.004. Epub 2022 Sep 13.
3
Androgen receptor activity in T cells limits checkpoint blockade efficacy.
Nature. 2022 Jun;606(7915):791-796. doi: 10.1038/s41586-022-04522-6. Epub 2022 Mar 23.
4
Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy.
Eur Urol. 2022 May;81(5):446-455. doi: 10.1016/j.eururo.2021.12.039. Epub 2022 Jan 17.
6
Cancer statistics, 2022.
CA Cancer J Clin. 2022 Jan;72(1):7-33. doi: 10.3322/caac.21708. Epub 2022 Jan 12.
7
Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment.
Cancer Cell. 2021 Nov 8;39(11):1464-1478.e8. doi: 10.1016/j.ccell.2021.09.005. Epub 2021 Oct 15.
8
Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer.
Nat Commun. 2021 Oct 1;12(1):5775. doi: 10.1038/s41467-021-26042-z.
9
An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer.
Nat Cell Biol. 2021 Sep;23(9):1023-1034. doi: 10.1038/s41556-021-00743-5. Epub 2021 Sep 6.
10
High fibroblast-activation-protein expression in castration-resistant prostate cancer supports the use of FAPI-molecular theranostics.
Eur J Nucl Med Mol Imaging. 2021 Dec;49(1):385-389. doi: 10.1007/s00259-021-05423-y. Epub 2021 Jul 5.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验